COMMUNIQUÉS West-GlobeNewswire
-
Venus Concept Announces Completion of Common Stock Sale and Short-Form Merger
01/04/2026 -
From The Earth and Illicit Launch Golden Ticket Giveaway This 4/20 Weekend
01/04/2026 -
Origin Health Unveils Newly Redesigned Website and Announces Open Registration for 2nd Annual Guardian Initiative Charity Golf Tournament
01/04/2026 -
Change in Orion Group Executive Team as of 8 April 2026 – Berkeley Vincent appointed Executive Vice President, Innovative Medicines
01/04/2026 -
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy
01/04/2026 -
Nephros Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning Expertise
01/04/2026 -
Merit Medical Acquires View Point Medical, Inc., expanding the Merit Therapeutic Oncology Portfolio
01/04/2026 -
Extendicare Acquires CBI Home Health
01/04/2026 -
Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)
01/04/2026 -
Noom Acquires Licensed 503A Pharmacy, Accelerating the Next Era of Preventive Care and Enabling Noom’s Expansion Beyond Weight Health
01/04/2026 -
J-Star Holding Announces Return of Jonathan Chiang as Chief Executive Officer
01/04/2026 -
Roto-Rooter Completes Acquisitions for Two Significant Territories
01/04/2026 -
Oncolytics Biotech® Completes Domicile Change to the United States
01/04/2026 -
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
01/04/2026 -
A Kaleidoscope Inspires the Foundation for Sarcoidosis “See Sarcoidosis” Global Campaign for Sarcoidosis Awareness Month
01/04/2026 -
AAVantgarde appoints Philip Lao as Senior Vice President of Business Development
01/04/2026 -
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
01/04/2026 -
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
01/04/2026 -
Tilray Brands Delivers Record Q3 Fiscal 2026 Results; Net Revenue Increases to $207 Million with 11% Organic Growth and Gross Profit Expands to $55 Million, Increasing 6% Year-Over-Year
01/04/2026
Pages